Myricx Bio

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

Health and bio

Acquired by NNovartis on July 6, 2026 · MSN.

TIMELINE · MONEY RAISED

Myricx Bio | 318 days from website to first raise on record

Raised $120M in 1 sourced round·1 signal before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

1. July 6, 2026
   Acquired by NNovartis
   Source: MSN
2. July 8, 2024
   Series A · $120M
   AAbingworth (lead), NNovo Holdings (lead), BBrandon Capital, BBritish Patient Capital, CCancer Research Horizons, EEli Lilly, SSofinnova Partners
   Source: startupintros.com
3. August 25, 2023
   Website created

Founders and team

• AB
  Andrew Bell Founder

  LinkedIn
• ET
  Ed Tate Founder

  LinkedIn
• RS
  Roberto Solari Founder

  LinkedIn
• FF
  Francesco Falciani Head of Bioinformatics
• GH
  Grant Hawthorne CFO
• JM
  Jonathon Marks-Bluth Vice President of Business Development
• PF
  Penny Fatato Vice President of Global Clinical Operations
• RR
  Richard Rutter Head of Biology
• RC
  Robin Carr Chief Technology Officer
• ZB
  Zahid Bashir Chief Medical Officer

Investors

• AAbingworthlead investor
• BBrandon Capital
• BBritish Patient Capital
• CCancer Research Horizons
• EEli Lilly
• NNovo Holdingslead investor
• SSofinnova Partners

Companies like Myricx Bio

• SStorm Therapeutics$56M Series B+ · Apr 2026
• CCellCentric$220M Series B+ · May 2026
• OOna Therapeutics$86.6M Series B+ · Oct 2026
• NNormunity$75M Series B+ · Jan 2025
• MMariana Oncology$175M Series B+ · Sep 2023
• VVelosbioSeries B+ · Aug 2026

Other companies backed by Abingworth

• NNouscom$135.04M Series B+ · Oct 2026
• RR1 Therapeutics$80.5M Series A · Sep 2026
• AAdvanCell$315M Series B+ · Jul 2026
• AAddition Therapeutics$100M Series A · Dec 2025
• GGlycomine$115M Series B+ · May 2025

Abingworth portfolio →